Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [18F]FDG PET/CT.
Humans
Carcinoma, Non-Small-Cell Lung
/ pathology
Male
Fluorodeoxyglucose F18
Female
Lung Neoplasms
/ pathology
Positron Emission Tomography Computed Tomography
/ methods
Lymphatic Metastasis
/ diagnostic imaging
Aged
Middle Aged
Carbonic Anhydrase IX
/ metabolism
Antigens, Neoplasm
/ metabolism
Aged, 80 and over
Adult
Lymph Nodes
/ pathology
Biomarkers, Tumor
/ metabolism
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
03
2024
accepted:
15
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Lung cancer is the leading cause of the global cancer incidence and mortality. It is important to obtain an accurate diagnosis of lymph-node metastasis before surgery to select the therapeutic strategy for non-small cell lung cancer (NSCLC) patients. Carbonic anhydrase 9 (CA9) is considered a marker of hypoxia and it has reported that CA9 is associated with tumor invasion and metastasis. In this study, the correlation between the CA9 expression for lymph-node metastases in NSCLC and [18F]FDG PET/CT results was investigated in order to clarify the efficacy of [18F]FDG PET/CT for detecting lymph-node metastases of NSCLC patients. Among the 564 patients who underwent surgical treatment for NSCLC between 2010 and 2016 at our hospital, a total of 338 patients who underwent preoperative [18F]FDG PET/CT were included in this study. CA9 expression was evaluated by immunochemistry. A lymph node with maximum standardized uptake value (SUVmax) ≥2.5 on [18F]FDG PET/CT was preoperatively defined as a metastatic lymph node. CA9 positivity was detected in 122 patients; the other 216 patients were CA9-negative. The CA9-positive NSCLC cases significantly associated with pleural invasion (p = 0.0063), pT-factor (p = 0.0080), pN-factor (p = 0.036) and pStage (p = 0.043). CA9-positive patients presented significantly poorer survival rate for OS than that of the CA9-negative patients (p = 0.0024). In the multivariable analysis, histological SCC and CA9 positivity were independent poor-prognosis factors for OS. For the total patient population, the sensitivity and specificity of [18F]FDG PET/CT for lymph-node metastases were 54% and 89%, respectively. In contrast, the sensitivity and specificity were particularly low in the CA9-positive SCC cases (36% and 69%, respectively). [18F]FDG PET/CT might not be useful for diagnosing lymph-node metastases of CA9-positive SCC cases of NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer is the leading cause of the global cancer incidence and mortality. It is important to obtain an accurate diagnosis of lymph-node metastasis before surgery to select the therapeutic strategy for non-small cell lung cancer (NSCLC) patients. Carbonic anhydrase 9 (CA9) is considered a marker of hypoxia and it has reported that CA9 is associated with tumor invasion and metastasis. In this study, the correlation between the CA9 expression for lymph-node metastases in NSCLC and [18F]FDG PET/CT results was investigated in order to clarify the efficacy of [18F]FDG PET/CT for detecting lymph-node metastases of NSCLC patients.
METHODS
METHODS
Among the 564 patients who underwent surgical treatment for NSCLC between 2010 and 2016 at our hospital, a total of 338 patients who underwent preoperative [18F]FDG PET/CT were included in this study. CA9 expression was evaluated by immunochemistry. A lymph node with maximum standardized uptake value (SUVmax) ≥2.5 on [18F]FDG PET/CT was preoperatively defined as a metastatic lymph node.
RESULT
RESULTS
CA9 positivity was detected in 122 patients; the other 216 patients were CA9-negative. The CA9-positive NSCLC cases significantly associated with pleural invasion (p = 0.0063), pT-factor (p = 0.0080), pN-factor (p = 0.036) and pStage (p = 0.043). CA9-positive patients presented significantly poorer survival rate for OS than that of the CA9-negative patients (p = 0.0024). In the multivariable analysis, histological SCC and CA9 positivity were independent poor-prognosis factors for OS. For the total patient population, the sensitivity and specificity of [18F]FDG PET/CT for lymph-node metastases were 54% and 89%, respectively. In contrast, the sensitivity and specificity were particularly low in the CA9-positive SCC cases (36% and 69%, respectively).
CONCLUSION
CONCLUSIONS
[18F]FDG PET/CT might not be useful for diagnosing lymph-node metastases of CA9-positive SCC cases of NSCLC.
Identifiants
pubmed: 39471162
doi: 10.1371/journal.pone.0312846
pii: PONE-D-24-08364
pmc: PMC11521239
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Carbonic Anhydrase IX
EC 4.2.1.1
CA9 protein, human
EC 4.2.1.1
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0312846Informations de copyright
Copyright: © 2024 Suzuki et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Thorac Dis. 2018 Nov;10(Suppl 31):S3648-S3654
pubmed: 30505548
Jpn J Clin Oncol. 2012 Mar;42(3):189-95
pubmed: 22210923
Lung Cancer. 2005 Feb;47(2):235-42
pubmed: 15639722
Cancer Res. 1996 Oct 1;56(19):4509-15
pubmed: 8813149
Clin Cancer Res. 2004 Dec 1;10(23):7925-33
pubmed: 15585626
Contemp Oncol (Pozn). 2021;25(1):45-52
pubmed: 33911981
Ann Thorac Cardiovasc Surg. 2017 Dec 20;23(6):291-297
pubmed: 28966230
Metabolites. 2017 Sep 16;7(3):
pubmed: 28926956
Clin Radiol. 2015 Jul;70(7):787-800
pubmed: 25917543
Nat Rev Cancer. 2003 Oct;3(10):721-32
pubmed: 13130303
Oncotarget. 2017 Jul 25;8(47):82437-82445
pubmed: 29137276
Lung. 2008 Sep-Oct;186(5):327-36
pubmed: 18670805
Hell J Nucl Med. 2022 May-Aug;25(2):196-204
pubmed: 35913866
J Thorac Oncol. 2010 Oct;5(10):1594-601
pubmed: 20736855
Head Neck. 2012 Oct;34(10):1395-402
pubmed: 22052623
Front Surg. 2022 Aug 23;9:944032
pubmed: 36090323
Surg Oncol. 2012 Sep;21(3):230-6
pubmed: 22197027
PLoS One. 2018 Jul 2;13(7):e0199970
pubmed: 29966011
J Immunol Res. 2019 Dec 01;2019:6263249
pubmed: 31886306
Cancer Biother Radiopharm. 2010 Apr;25(2):149-54
pubmed: 20423227
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2051-7
pubmed: 24990401
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Sci Rep. 2023 Jan 28;13(1):1565
pubmed: 36709375
Br J Pharmacol. 2016 Feb;173(4):635-48
pubmed: 26013585
Cancer Res. 2004 Mar 15;64(6):2054-61
pubmed: 15026343
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Thorac Oncol. 2014 Oct;9(10):1485-93
pubmed: 25170642
BMC Pulm Med. 2015 Mar 08;15:20
pubmed: 25880540
Diagnostics (Basel). 2023 May 29;13(11):
pubmed: 37296745
N Engl J Med. 2011 Feb 17;364(7):656-65
pubmed: 21323543
Respiration. 2003 Sep-Oct;70(5):500-6
pubmed: 14665776
Eur J Cardiothorac Surg. 2013 Jul;44(1):83-7
pubmed: 23233074
Cancer Res Treat. 2016 Jan;48(1):125-32
pubmed: 25761481
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
J Urol. 2007 Aug;178(2):677-82
pubmed: 17574616
J Cell Sci. 2011 Apr 1;124(Pt 7):1077-87
pubmed: 21363891
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1563-1579
pubmed: 31575553